FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2596596216> ?p ?o ?g. }

• W2596596216 endingPage "777" @default.
• W2596596216 startingPage "777" @default.
• W2596596216 abstract "Abstract Among the clinical subtypes of diffuse large B-cell lymphoma, central nervous system (CNS) lymphomas, both primary (PCNSL) and secondary (SCNSL), are generally associated with the worst prognosis. Moreover, PCNSL typically exhibits multifocal dissemination, prompting its description as a whole brain disease. An accumulation of genomic data suggests that aberrant NF-kB pro-survival signaling may be a critical factor in the pathogenesis of CNS lymphoma. To date, however, there has been an absence of mechanistic studies to interrogate the mediators and significance of NF-kB activation in CNS lymphoma invasion. Recently our lab derived the first panel of xenografts yet established from PCNSL patients (n=7), and defined their invasive properties in murine models. These novel model systems provide a unique opportunity to study key regulatory mechanisms as well as novel targeted therapies of CNS lymphoma invasion and growth within the brain. We determined that the intracranial growth patterns of the xenografts can be classified based upon reproducible patterns of invasiveness. Two xenografts derived from SCNSL failed to infiltrate brain parenchyma or to migrate to the contralateral hemisphere; instead these tumors exhibited solely a meningeal dissemination pattern, largely growing in the ventricles. By contrast, five of the xenografts exhibited diffuse brain invasion into bilateral hemispheres. In addition, we noted that CNS lymphoma xenografts with an invasive phenotype can be sub-divided phenotypically into moderately vs. highly invasive tumors. After standard injection of 200,000 tumor cells/brain, the highly invasive lymphomas were reproducibly lethal to mice within 3 weeks post-implantation and yielded ~ 1X106 lymphoma cells/brain at necropsy. Under identical conditions, the moderately-invasive lymphoma xenografts were lethal to mice within 1-3 months and yielded between 3-5 X106lymphoma cells/brain. Notably each of the highly invasive CNS lymphoma xenografts were derived from CNS lymphomas that contained the activating L265P mutation of MYD88 (activator of NF-kB via IRAK1/4) and/or Y196H mutation of CD79B (activator of NF-kB), whereas the non-invasive xenografts contained wild type MYD88 and CD79B. We analyzed RNA-seq expression data of these xenograft samples to evaluate relationship of individual genes and signaling pathways with the distinct subclasses of CNS lymphomas in terms of invasiveness. Upregulated signatures in the pro-invasive phenotype are significantly enriched with NF-kB target genes (http://lymphochip.nih.gov/signaturedb/) (FDR<3e-4). For example, as expected, the most invasive xenografts derived from CNS lymphoma specimens expressed high RelA (p65) and NFKB1, core components of the NF-kB multimeric complex. The invasive CNS lymphoma xenografts also exhibited upregulation of MYD88, SYK and PIM1/2, inducers of NF-kB activation. Conversely, the non-invasive xenografts expressed a signature of predominantly non-NF-kB-induced genes including SPRY1/2 (negative regulators of receptor tyrosine kinases) and TIMP2 (negative regulator of invasion). Gene set enrichment analysis confirmed a similar pattern of transcripts expressed in highly invasive PCNSL isolated from diagnostic specimens in patients (N=23; FDR <0.017). Given that the L265P mutation of MYD88 represents a candidate key driver of NF-kB activation in CNS lymphoma, we evaluated the preclinical efficacy of AZ1495, a novel and potent inhibitor of IRAKs. We demonstrated CNS penetration of AZ1495 after PO administration to mice with intracranial lymphoma xenografts, yielding a mean brain/plasma partition coefficient of 0.8. AZ1495 potently antagonized NF-kB activation as demonstrated by p-p65 immunoblot analysis of tumor lysates isolated from murine CNS lymphoma xenografts, within 3 hrs of administration. AZ1495 monotherapy resulted in > 2-fold delay in both intracranial plus spinal progression in a dissemination model of CNS lymphoma using L265P mutant OCI-LY10 cells engineered for bioluminescence (p<0.01). Finally, AZ1495 treatment resulted in a >2-fold increase in median OS in a patient-derived model of L265P mutant PCNSL. These results support the preclinical utility of these models to dissect impact of NF-kB inhibition on CNS lymphoma progression as well as the clinical potential of IRAK antagonism as a means to target NF-kB activation in L265P mutant CNS lymphomas. Disclosures Anjum: Astra Zeneca: Employment. Drew:Astra Zeneca: Employment. Degorce:Astra Zeneca: Employment. Dillman:Astra Zeneca: Employment. Mayo:Astra Zeneca: Employment. Rubenstein:Celgene: Research Funding; Genentech: Research Funding." @default.
• W2596596216 created "2017-03-23" @default.
• W2596596216 creator A5002206377 @default.
• W2596596216 creator A5005822663 @default.
• W2596596216 creator A5010517370 @default.
• W2596596216 creator A5020303646 @default.
• W2596596216 creator A5020403670 @default.
• W2596596216 creator A5035319804 @default.
• W2596596216 creator A5036950255 @default.
• W2596596216 creator A5047297990 @default.
• W2596596216 creator A5050325886 @default.
• W2596596216 creator A5060120275 @default.
• W2596596216 creator A5063781367 @default.
• W2596596216 creator A5068387763 @default.
• W2596596216 creator A5082818365 @default.
• W2596596216 creator A5090795154 @default.
• W2596596216 date "2016-12-02" @default.
• W2596596216 modified "2023-09-26" @default.
• W2596596216 title "Targeting NF-KB Activation in Novel Intracranial Models of CNS Lymphoma" @default.
• W2596596216 doi "https://doi.org/10.1182/blood.v128.22.777.777" @default.
• W2596596216 hasPublicationYear "2016" @default.
• W2596596216 type Work @default.
• W2596596216 sameAs 2596596216 @default.
• W2596596216 citedByCount "2" @default.
• W2596596216 countsByYear W25965962162021 @default.
• W2596596216 countsByYear W25965962162023 @default.
• W2596596216 crossrefType "journal-article" @default.
• W2596596216 hasAuthorship W2596596216A5002206377 @default.
• W2596596216 hasAuthorship W2596596216A5005822663 @default.
• W2596596216 hasAuthorship W2596596216A5010517370 @default.
• W2596596216 hasAuthorship W2596596216A5020303646 @default.
• W2596596216 hasAuthorship W2596596216A5020403670 @default.
• W2596596216 hasAuthorship W2596596216A5035319804 @default.
• W2596596216 hasAuthorship W2596596216A5036950255 @default.
• W2596596216 hasAuthorship W2596596216A5047297990 @default.
• W2596596216 hasAuthorship W2596596216A5050325886 @default.
• W2596596216 hasAuthorship W2596596216A5060120275 @default.
• W2596596216 hasAuthorship W2596596216A5063781367 @default.
• W2596596216 hasAuthorship W2596596216A5068387763 @default.
• W2596596216 hasAuthorship W2596596216A5082818365 @default.
• W2596596216 hasAuthorship W2596596216A5090795154 @default.
• W2596596216 hasConcept C142724271 @default.
• W2596596216 hasConcept C169760540 @default.
• W2596596216 hasConcept C196822366 @default.
• W2596596216 hasConcept C2778559949 @default.
• W2596596216 hasConcept C2779338263 @default.
• W2596596216 hasConcept C2780942790 @default.
• W2596596216 hasConcept C2781173314 @default.
• W2596596216 hasConcept C502942594 @default.
• W2596596216 hasConcept C529278444 @default.
• W2596596216 hasConcept C71924100 @default.
• W2596596216 hasConcept C86803240 @default.
• W2596596216 hasConceptScore W2596596216C142724271 @default.
• W2596596216 hasConceptScore W2596596216C169760540 @default.
• W2596596216 hasConceptScore W2596596216C196822366 @default.
• W2596596216 hasConceptScore W2596596216C2778559949 @default.
• W2596596216 hasConceptScore W2596596216C2779338263 @default.
• W2596596216 hasConceptScore W2596596216C2780942790 @default.
• W2596596216 hasConceptScore W2596596216C2781173314 @default.
• W2596596216 hasConceptScore W2596596216C502942594 @default.
• W2596596216 hasConceptScore W2596596216C529278444 @default.
• W2596596216 hasConceptScore W2596596216C71924100 @default.
• W2596596216 hasConceptScore W2596596216C86803240 @default.
• W2596596216 hasIssue "22" @default.
• W2596596216 hasLocation W25965962161 @default.
• W2596596216 hasOpenAccess W2596596216 @default.
• W2596596216 hasPrimaryLocation W25965962161 @default.
• W2596596216 hasRelatedWork W2042200952 @default.
• W2596596216 hasRelatedWork W2135722038 @default.
• W2596596216 hasRelatedWork W2373168960 @default.
• W2596596216 hasRelatedWork W3007870809 @default.
• W2596596216 hasRelatedWork W3023845159 @default.
• W2596596216 hasRelatedWork W42087377 @default.
• W2596596216 hasRelatedWork W4231035251 @default.
• W2596596216 hasRelatedWork W4235366215 @default.
• W2596596216 hasRelatedWork W4244744752 @default.
• W2596596216 hasRelatedWork W2464789773 @default.
• W2596596216 hasVolume "128" @default.
• W2596596216 isParatext "false" @default.
• W2596596216 isRetracted "false" @default.
• W2596596216 magId "2596596216" @default.
• W2596596216 workType "article" @default.